| Literature DB >> 30728395 |
I L Pacheco1, N Abril2, R Zafra3, N Morales-Prieto2, V Molina Hernández1, M T Ruiz1, R Perez-Caballero3, A Martínez-Moreno3, J Pérez4.
Abstract
The aim of this study was to validate reference genes for gene normalisation using qRT-PCR in hepatic lymph nodes (HLN) and livers from sheep infected with Fasciola hepatica during early and late stages of infection. To this end, a comprehensive statistical approach (RefFinder) encompassing four different methods of analysis (geNorm, BestKeeper, ΔCt method and NormFinder) was used to validate ten candidate reference genes. Stability analysis of gene expression followed by pairwise variation (Vn/Vn + 1) analysis revealed that PGK1, HSP90AA1 and GYPC were the most stable reference genes and suitable for qRT-PCR normalisation in both HLN and liver tissues. These three genes were validated against FoxP3, IL-10, TGF-β, TNF-α and IL-1β genes in the HLN tissue of sheep vaccinated with Cathepsin L1 from F. hepatica and unvaccinated infected and uninfected controls during early stages of infection. In the liver, the three reference genes were validated against TNF-α and IL-1β during chronic stages of infection with F. hepatica and in uninfected controls. Our study is the first to evaluate and validate sheep reference genes in order to provide tools for monitoring cytokines in Fasciola hepatica infected sheep target organs. Our results present an approach to elucidate the role of different cytokines in F. hepatica vaccinated and infected sheep.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30728395 PMCID: PMC6365638 DOI: 10.1038/s41598-018-37672-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1RNA integrity. Gel images of RNA samples and the RIN values (under the green lines) obtained by the Agilent Bioanalyzer. RIN = RNA Integrity Number; L = RNA Ladder; dpi: days post-infection; wpi: weeks post-infection. Green line in: Bioanalyzer internal marker.
Primers used in this work.
| Targeta | Accesion numbera | Primers sequencesb 5′–3′ | Primers Tm (°C)c | Amplified product length (bp)d | Amplification efficiency | References |
|---|---|---|---|---|---|---|
| (R2)e | ||||||
|
| NM_001024860.1 | F 5′-CCACGCTCTTCTGCCTGCTGCACTTCGG-3′ | 73.1 | 146 | 0.996 | Pacheco |
| R 5′-AACGTGGGCTACCGGCTTGTTATTTGAGGC-3′ | 73.6 | (99.56) | ||||
|
| NM_001009465.2 | F 5′-GAAGCTGAGGAGCCGTGCCTACGAACA-3′ | 68.8 | 185 | 1.001 | Pacheco |
| R 5′-CCAGCACCAGGGATTTTTGCTCTCTGTCC-3′ | 69.0 | (99.85) | ||||
|
| NM_001144947.1 | F 5′-GCCCATCTGGCTGGGAAGATGGCCCAAACC-3′ | 76.5 | 166 | 0.991 | Pacheco |
| R 5′- AGAGGTGCCTCCGCACGGCAAACAGG-3′ | 76.2 | (99.16) | ||||
|
| NM_001009327.1 | F 5′-TCAGCCGTGCTCTGTTGCCTGGTCTTCC-3′ | 73.8 | 124 | 0.999 | Pacheco |
| R 5′- GGACGTCCCGCAGCATGTGGGGCAG-3′ | 73.5 | (99.9) | ||||
|
| NM_001009400.1 | F 5′- GGGCTTTCGCCTCAGTGCCCACTGTTC-3′ | 73.8 | 151 | 1.009 | Pacheco |
| R 5′- CAGAGGGGTGGCCATGAGGAGCAGG-3′ | 73.8 | (99.9) | ||||
|
| NM_001142516.1 | F 5′-GTGAAGGGGAAGCGGGTCGTCATGAGAG-3′ | 72.9 | 99 | 1.002 | Pacheco |
| R 5′-GCTTGGAACAGCAGCCTTGATCCTCTGG-3′ | 72.1 | (99.43) | ||||
|
| NM_001009284.2 | F 5′-CAAGACACCCGCCAGAAGATGGAAAGC-3′ | 71.6 | 180 | 0.989 | Pacheco |
| R 5′-GGAGTGAACTCAGCGTGGGACAGAAGG-3′ | 70.3 | (99.91) | ||||
|
| XM_004017413.2 | F 5′-CGGCTGCTGCCCGTGCTGGTGCCAT-3′ | 77.7 | 191 | 1.002 | Pacheco |
| R 5′-TTCGCTGGCGCCCACCTTGTCTCCGGTC-3′ | 77.1 | (99.81) | ||||
|
| NM_001093780.1 | F 5′-CGGGCGAGAGCAACGAAGCACAGAGAGC-3′ | 74.0 | 161 | 1.004 | Pacheco |
| R 5′-CCAGGTCCCCCGATGCACCCATGATG-3′ | 74.2 | (99.82) | ||||
|
| XM_012097183.1 | F 5′-CCATGAGTTTGATGCCGTGGTGGTCGGTGC-3′ | 70.7 | 184 | 1.006 | Pacheco |
| R 5′-CCGCCAGTTGTCCTCCTCCATGTTCCCCA −3′ | 70.4 | (99.51) | ||||
|
| NM_001009784.1 | F 5′-GCGTGATGGTGGGCATGGGCCAGAAGG-3′ | 76.0 | 170 | 1.003 | This work |
| R 5′-GGGGGCCACACGCAGCTCGTTGTAGAAGG-3′ | 75.7 | (99.99) | ||||
|
| XM_004017995.3 | F 5′-GCCGCCCCTGGAAGGAGACGACGACACG-3′ | 71.1 | 130 | 1.005 | This work |
| R 5′-GCCAGGCGAGCCTCGGCAGCGCTCA-3′ | 72.0 | (99.53) | ||||
|
| XM_004004772.3 | F 5′-TGCCCCGCACCGGCCAGCGATGAG-3′ | 79.2 | 110 | 1.006 | This work |
| R 5′-GGTCGGGCTCTGGGGTCCAAAGGGGCGTC-3′ | 79.3 | (99.85) | ||||
|
| XM_015103904.1 | F 5′-CTTCCGCGCCGACTTCTCCGACAAC-3′ | 72.4 | 185 | 1.004 | This work |
| R 5′-GCAGCGTGATCTCCCGTTCATACCACACC-3′ | 72.8 | (99.89) | ||||
|
| XM_012101347.2 | F 5′-CCAGGACGCCACGGCCGAGGAGGAGGG-3′ | 79.1 | 112 | 0.997 | This work |
| R 5′-TGGCCGCAGCCGCGTCCCACCCCTTC-3′ | 79.8 | (99.58) |
aGene symbols and accession numbers are according to the NCBI Gene database, bSequence of forward (F) and reverse (R) primers, cMelting temperature (°C) calculated by the Oligo 7 software, dPCR product size in base pair (bp), eThe real-time PCR efficiencies (E) were calculated from each efficiency curve according to the equation E = 10(−1/slope) −1. E is in the range from 0 (minimum value) to 1 (maximum and optimum). i.e. E = 1 is equal to 100% efficiency.
Figure 2Confirmation of gene specificity and amplicon size. (A) Agarose gel of qRT-PCR products for each gene with the expected size. Equal amounts of cDNA from any animal were mixed and amplified with each primer pair and PCR products loaded on a 2% agarose gel. A standard DNA molecular weight ladder was loaded. Gel has been cropped to show only relevant information; the full-length gel is shown in Supp. Figure 1. (B) Melting curves of the 10 putative reference genes showing a single peak. The Tm values of each amplification product are shown over the peaks.
Figure 3Distribution of Ct values for candidate reference genes. (A) Both tissues, HLN and liver Ct values were analyzed together. (B) HLN data analysis. (C) Liver data analysis. Boxes: range of Ct values; black center line: median Ct; cross: mean score; upper and lower hinges: 75 and 25 percentiles; whiskers: largest/smallest Ct values within a distance of 1.5 times IQR (Interquartile range) from the upper and lower hinges.
Stability ranking of candidate reference genes.
| GeNorm | NormFinder | Bestkeeper | ΔCt Method | RefFinder | |||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
| 0.608 |
| 0.135 |
| 0.630 |
| 1.330 |
|
|
|
| 0.608 |
| 0.546 |
| 1.020 |
| 1.400 |
|
|
|
| 0.741 |
| 0.700 |
| 1.760 |
| 1.440 |
|
|
|
| 0.775 |
| 0.771 |
| 0.710 |
| 1.490 |
|
|
|
| 0.812 |
| 0.892 |
| 1.310 |
| 1.530 |
|
|
|
| 0.902 |
| 0.935 |
| 0.640 |
| 1.630 |
|
|
|
| 1.038 |
| 0.941 |
| 1.070 |
| 1.640 |
|
|
|
| 1.168 |
| 1.190 |
| 0.710 |
| 1.740 |
|
|
|
| 1.261 |
| 1.609 |
| 1.060 |
| 1.940 |
|
|
|
| 1.816 |
| 3.970 |
| 3.220 |
| 4.040 |
|
|
|
| |||||||||
|
| 0.420 |
| 0.393 |
| 0.450 |
| 0.760 |
|
|
|
| 0.420 |
| 0.423 |
| 0.440 |
| 0.780 |
|
|
|
| 0.530 |
| 0.440 |
| 1.340 |
| 0.790 |
|
|
|
| 0.550 |
| 0.481 |
| 0.450 |
| 0.820 |
|
|
|
| 0.586 |
| 0.510 |
| 0.780 |
| 0.830 |
|
|
|
| 0.644 |
| 0.530 |
| 0.500 |
| 0.870 |
|
|
|
| 0.692 |
| 0.618 |
| 0.810 |
| 0.920 |
|
|
|
| 0.738 |
| 0.731 |
| 0.270 |
| 0.950 |
|
|
|
| 0.774 |
| 0.779 |
| 0.330 |
| 0.990 |
|
|
|
| 0.923 |
| 1.434 |
| 0.640 |
| 1.520 |
|
|
|
| |||||||||
|
| 0.426 |
| 0.294 |
| 0.530 |
| 0.920 |
|
|
|
| 0.426 |
| 0.318 |
| 0.560 |
| 0.940 |
|
|
|
| 0.533 |
| 0.331 |
| 0.950 |
| 0.950 |
|
|
|
| 0.564 |
| 0.516 |
| 0.690 |
| 1.010 |
|
|
|
| 0.642 |
| 0.554 |
| 0.780 |
| 1.030 |
|
|
|
| 0.684 |
| 0.588 |
| 0.330 |
| 1.070 |
|
|
|
| 0.758 |
| 0.666 |
| 0.410 |
| 1.080 |
|
|
|
| 0.886 |
| 1.190 |
| 0.510 |
| 1.370 |
|
|
|
| 0.984 |
| 1.371 |
| 0.330 |
| 1.500 |
|
|
|
| 1.187 |
| 1.926 |
| 1.270 |
| 2.000 |
|
|
Figure 4Determination of the optimal number of reference genes for normalization. The geNorm algorithm was used to determine the pair-wise variation value (Vn/n + 1) from the Ct values obtained in HLN, liver and both tissues altogether.
Figure 5Gene expression of FoxP3 and regulatory cytokines in HLN. aIndicates significant differences in comparison with group 3 (negative control).
Figure 6Gene expression of proinflammatory cytokines in HLN. aIndicates significant differences in comparison with group 3 (negative control).
Figure 7Gene expression of proinflammatory cytokines in liver. aIndicates significant differences (p < 0.001) in comparison with group 5 (uninfected control).
Figure 8Timing of immmunisations, infections and sacrifice of groups one to five.